**Novel biomarkers for prostate cancer: The research continues**

**Poster Session 09**

**Location:** Blue Area, Room 2 (Level 0)

**Chairs:** I. Heidegger, Innsbruck (AT)  
P.B. Östergren, Herlev (DK)  
K.A. Tasken, Oslo (NO)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**99**

**CHD1 deletion is an independent predictor of poor prognosis by increased metastasis in both PTEN-deficient and -intact prostate cancer**

By: Oh-Hohenhorst S.J. 1, Tilki D. 1, Matuszcak C. 2, Tennstedt P. 1, Kluth M. 3, Baumgart S. 4, Johnsen S.A. 4, Sirma H. 3, Simon R. 3, Lange T. 5

1University Hospital Hamburg-Eppendorf, Martini-Klinik, Prostate Cancer Center, Hamburg, Germany, 2University Hospital Hamburg-Eppendorf, University Cancer Center Hamburg, Hamburg, Germany, 3University Hospital Hamburg-Eppendorf, Dept. of Pathology, Hamburg, Germany, 4University Medical Center Göttingen, Dept. of General, Visceral and Pediatric Surgery, Göttingen, Germany, 5University Hospital Hamburg-Eppendorf, Dept. of Anatomy and Experimental Morphology, Hamburg, Germany

---

**100**

**Aggressive prostate cancer by the loss of male specific histone demethylase ‘KDM5D’**

By: Komura K. 1, Inamoto T. 2, Ibuki N. 2, Sweeney C. 3, Azuma H. 2, Kantoff P. 1

1Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York, United States of America, 2Osaka Medical College, Dept. of Urology, Takatsuki city, Japan, 3Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America

---

**101**

**Positive status for STAT5 locus amplification in conjunction with STAT5 protein expression is a powerful predictor of recurrence after radical prostatectomy**

By: Nevalainen M. 1, Haddad B. 2, Erickson A.M. 3, Udhane V. 4, Laviolette P. 5, Aaltonen E. 6, Pavela M. 6, See W. 7, Kallajoki M. 6, Mirtti T. 8

1Medical College of Wisconsin, Dept. of Pathology, Dept. of Pharmacology & Toxicology, and Medical College of Wisconsin Cancer Center, Milwaukee, United States of America, 2Georgetown University, Dept. of Oncology and Lombardi Comprehensive Cancer Center, Washington DC, United States of America, 3University of Helsinki, and Institute of Molecular Medicine Finland (FIMM), Dept. of Pathology, Medicum, Helsinki, Finland, 4Medical College of Wisconsin, Dept. of Pathology and Medical College of Wisconsin Cancer Center, Milwaukee, United States of America, 5Medical College of Wisconsin, Dept. of Radiology and Medical College of Wisconsin Cancer Center, Milwaukee, United States of America, 6Medical College of Wisconsin, Dept. of Pathology, 7Medical College of Wisconsin, Department of Pathology, 8Medical College of Wisconsin, Dept. of Pathology and Medical College of Wisconsin Cancer Center.
FABP5 RNA expression as potential marker in TMPRSS2:ERG fusion negative prostate cancer


Mannheim Medical Center, Dept. of Urology, Mannheim, Germany; Mannheim Medical Center, Institute of Pathology, Mannheim, Germany; German Cancer Research Center, Dept. of Signalling and Functional Genomics, Heidelberg, Germany

Identification and evaluation of serum protein biomarkers for organ confined prostate cancer

By: McArdle A., Tonry C., Fan Y., Inzitari R., Rooney R., Brian B., Parnell A., Finn S., Pennington S.

Atturos, Conway Institute University College Dublin, Dublin, Ireland; Conway Institute, University College Dublin, Dublin, Ireland; NOVA, University College Dublin, Dublin, Ireland; University College Dublin, School of Maths, Dublin, Ireland; Trinity College Dublin, School of Medicine, Dublin, Ireland; Atturos, Conway Institute, University College Dublin, Dublin, Ireland

Potential new minimally-invasive diagnostic biomarkers for prostate cancer

By: Bjerre M.T., Strand S., Fredsøe J., Høyer S., Mortensen M., Borre M., Sørensen K.

Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark; Aarhus University Hospital, Institute of Pathology, Aarhus, Denmark; Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark

Comparison of cell cycle progression (CCP) score to two IHC markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy


CHU Reims, Dept. of Urology, Reims, France; GRC n°5, ONCOTYPE-URO, Institut Universitaire de Cancérologie, UPMC Sorbonne Université, Paris, F-75020, France; CeRePP, Paris, F-75020, France; ONCOTYPE-URO, Paris, France; Hopital Tenon, AP-HP, UPMC Sorbonne Université, Paris, F-75020, France; Dept. of Urology, Paris, France; Hopital Pitié-Salpêtrière, AP-HP, UPMC Sorbonne Université, Paris, F-75013, France; Dept. of Urology, Paris, France; Academic Department of Pathology, Hopital Pitie-Salpetriere, AP-HP, UPMC Sorbonne Université, Paris, F-75013, France; Dept. of Pathology, Paris, France; Hopital Tenon, AP-HP, UPMC Sorbonne Université, Paris,
106 Association of NRP2 and EGFR co-expression with cancer-specific survival in prostate cancer and the influence of NRP2-depletion combined with EGFR-inhibition on cell functioning in cisplatin-sensitive and -resistant DU145 prostate cancer cell lines

By: Borkowetz A., Fuessel S., Erdmann K., Schulz A., Baretton G., Froehner M., Toma M., Muders M., Wirth M.

1Technische Universität Dresden, Dept. of Urology, Dresden, Germany, 2OncoRay National Center for Radiation Research in Oncology, Dept. of Radiology, Dresden, Germany, 3Technische Universität Dresden, Dept. of Pathology, Dresden, Germany, 4University of Bonn, Dept. of Pathology, Bonn, Germany

107 Integrative analysis of the proteome in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression


University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland

108 A multivariate survival analysis of tumour micro-environment markers reveals an independent prognostic subgroup in matched prostate cancer cohorts


1UZ Leuven, Dept. of Urology, Leuven, Belgium, 2Université Libre de Bruxelles, Dept. of Pathology/CMMI, Brussels, Belgium, 3KU Leuven, Dept. of Cellular and Molecular Medicine, Leuven, Belgium

109 A novel risk score (P-score) based on a 3-gene signature for survival prognosis of newly diagnosed prostate cancer patients

By: Peng Z., Chatzianastasio D., Söderdahl F., Honek J., Cao R., Meisgen F., Yachnin J., Nilsson S., Li C.

1Karolinska Institutet, Dept. of Oncology and Pathology, Stockholm, Sweden, 2Danderyd Hospital, Dept. of Pathology and Cytology, Stockholm, Sweden, 3Statisticon AB, Dept. of Statistical analyse, Stockholm, Sweden, 4Chundsell Medical AB, Dept. of Development, Stockholm, Sweden, 5Karolinska University Hospital, Dept. of Oncology, Stockholm, Sweden
110 Exploring the role of gut microbiota and prostate cancer

By: Munukka E.¹, Gunell M.¹, Pietilä S.², Knaapila J.³, Rintala A.¹, Kallio H.¹, Lamminen T.⁴, Eerola E.¹, Huovinen P.⁵, Hakanen A.¹, Boström P.³
¹Turku University Hospital, Dept. of Microbiology and Genetics, Turku, Finland, ²University of Turku, Turku Center for Biotechnology, Turku, Finland, ³Turku University Hospital and University of Turku, Dept. of Urology, Turku, Finland, ⁴Turku University Hospital, Dept. of Urology, Turku, Finland, ⁵University of Turku, Dept. of Biomedicine, Medical Microbiology and Immunology, Turku, Finland

111 Transcribed ultraconserved region Uc.63+ promotes resistance to docetaxel through AR signaling and a promising serum biomarker for docetaxel treatment in prostate cancer

By: Sekino Y.¹, Sakamoto N.², Goto K.¹, Honma R.², Shigematsu Y.¹, Sentani K.², Oue N.², Teishima J.¹, Yasui W.², Matsubara A.¹
¹Institute of Biomedical & Health Sciences Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Institute of Biomedical & Health Sciences Hiroshima University, Dept. of molecular pathology, Hiroshima, Japan

112 The mutational landscape of prostate cancer linked with pre-docetaxel LDH determines docetaxel treatment in mCRPC

By: Hiew K.¹, Hart C.A.¹, Ali A.¹, Lau M.², Ramani V.A.C.², Sangar V.², Maddineni S.², Elliott T.³, Brown M.¹, Clarke N.W.²
¹The University of Manchester, GUCR Group, Division of Cancer Sciences, Manchester, United Kingdom, ²The Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, ³The Christie Hospital NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom

Summary
I. Heidegger, Innsbruck (AT)